David joined Genomics in September 2024 as President, where he assumed responsibility for the company's operations, with a strategic focus on scaling its existing businesses.
David transitioned to Genomics from IQVIA, a Fortune 500 corporation specializing in Human Data Science. During his tenure at IQVIA as Senior Vice President and a member of the Global Executive Leadership Group, he led the Commercial Engagement Services Division, driving advancements in patient and commercial engagement through the application of artificial intelligence, machine learning, and advanced data analytics.
His prior leadership roles at IQVIA include overseeing Biotech Commercial teams across Europe and directing business development initiatives for Real World Evidence throughout the U.S., EMEA, and Asia Pacific regions.
Earlier in his career, David held diverse leadership and advisory positions within various healthcare-focused enterprises.